Related Experiment Videos

[Inhibition by pentoxifylline of procoagulant activity produced by endotoxin-active monocytes]

D de Prost1, V Ollivier, J Hakim

  • 1Laboratoire d'immunologie et d'hématologie, U INSERM 294, CHU Xavier Bichat, Paris.

Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales
|January 1, 1992
PubMed

Insights

Pentoxifylline, a drug, inhibits monocyte procoagulant activity by increasing cyclic AMP levels. This finding reveals a novel mechanism for regulating blood coagulation during inflammation.

Area of Science:

  • Immunology
  • Hematology
  • Pharmacology

Context:

  • Monocytes play a key role in initiating blood coagulation via tissue factor expression.
  • Monocyte procoagulant activity is implicated in inflammatory responses in vivo.

Purpose:

  • To investigate the effect of pentoxifylline on monocyte procoagulant activity.
  • To elucidate the mechanism underlying pentoxifylline's inhibitory action.

Summary:

  • Pentoxifylline, a methylxanthine derivative, was found to inhibit endotoxin-induced procoagulant activity in monocytes in vitro.
  • This inhibition correlated with an early rise in intracellular cyclic AMP (cAMP) levels.
  • The effect of pentoxifylline was mimicked by other compounds that elevate cAMP.

Impact:

  • Suggests that pentoxifylline's suppressive effect on monocyte procoagulant activity is, at least partly, mediated by increased intracellular cAMP.
  • Provides potential therapeutic insights for conditions involving monocyte-driven coagulation and inflammation.

Related Concept Videos